Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.03
- Piotroski Score 2.00
- Grade Buy
- Symbol (CVKD)
- Company Cadrenal Therapeutics, Inc. Common Stock
- Price $14.01
- Changes Percentage (-3.38%)
- Change -$0.49
- Day Low $14.00
- Day High $14.99
- Year High $32.55
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/10/2025
- Fiscal Year End N/A
- Average Stock Price Target $32.00
- High Stock Price Target $32.00
- Low Stock Price Target $32.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-8,357,086
Income Statement
Quarterly
Annual
Latest News of CVKD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now
An analysis of top new penny stocks to buy includes Cadrenal Therapeutics, Inc. (CVKD) amid US recession fears. CVKD, a biopharmaceutical company, is developing an anticoagulant drug with promising cl...
By Yahoo! Finance | 3 months ago
